Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Sep;52(3):403–405. doi: 10.1038/bjc.1985.208

Resistance of human T-CFUcs to activated cyclophosphamide: a feature common with critical marrow stem cells?

J E Byfield, P M Calabro-Jones
PMCID: PMC1977205  PMID: 3876106

Full text

PDF
403

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byfield J. E., Calabro-Jones P. M. Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents. Nature. 1981 Nov 19;294(5838):281–283. doi: 10.1038/294281a0. [DOI] [PubMed] [Google Scholar]
  2. Byfield J. E., Murnane J., Ward J. F., Calabro-Jones P., Lynch M., Kulhanian F. Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents. Br J Cancer. 1981 May;43(5):669–683. doi: 10.1038/bjc.1981.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fenselau C., Kan M. N., Rao S. S., Myles A., Friedman O. M., Colvin M. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res. 1977 Aug;37(8 Pt 1):2538–2543. [PubMed] [Google Scholar]
  4. Körbling M., Hess A. D., Tutschka P. J., Kaizer H., Colvin M. O., Santos G. W. 4-hydroperoxycyclophosphamide: a model for eliminating residual human tumour cells and T-lymphocytes from the bone marrow graft. Br J Haematol. 1982 Sep;52(1):89–96. doi: 10.1111/j.1365-2141.1982.tb03864.x. [DOI] [PubMed] [Google Scholar]
  5. Lerman S. P., Weidanz W. P. The effect of cyclophosphamide on the ontogeny of the humoral immune response in chickens. J Immunol. 1970 Sep;105(3):614–619. [PubMed] [Google Scholar]
  6. Murnane J. P., Byfield J. E., Ward J. F., Calabro-Jones P. Effects of methylated xanthines on mammalian cells treated with bifunctional alkylating agents. Nature. 1980 May 29;285(5763):326–329. doi: 10.1038/285326a0. [DOI] [PubMed] [Google Scholar]
  7. Sharkis S. J., Santos G. W., Colvin M. Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide. Blood. 1980 Mar;55(3):521–523. [PubMed] [Google Scholar]
  8. Smith I. E., Evans B. D., Harland S. J., Millar J. L. Autologous bone marrow rescue is unnecessary after very-high-dose cyclophosphamide. Lancet. 1983 Jan 1;1(8314-5):76–77. doi: 10.1016/s0140-6736(83)91617-3. [DOI] [PubMed] [Google Scholar]
  9. Stockman G. D., Heim L. R., South M. A., Trentin J. J. Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol. 1973 Jan;110(1):277–282. [PubMed] [Google Scholar]
  10. Turk J. L., Parker D. Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev. 1982;65:99–113. doi: 10.1111/j.1600-065x.1982.tb00429.x. [DOI] [PubMed] [Google Scholar]
  11. Turk J. L., Parker D., Poulter L. W. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology. 1972 Oct;23(4):493–501. [PMC free article] [PubMed] [Google Scholar]
  12. Wagner T., Peter G., Voelcker G., Hohorst H. J. Characterization and quantitative estimation of activated cyclophosphamide in blood and urine. Cancer Res. 1977 Aug;37(8 Pt 1):2592–2596. [PubMed] [Google Scholar]
  13. Winkelstein A. Murine B-lymphocyte colony formation: the effects of cyclophosphamide and azathioprine. Immunology. 1982 Aug;46(4):827–832. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES